Pro-Dex, Inc. (PDEX) vs Prelude Therapeutics Incorporated (PRLD)

A side-by-side comparison of Pro-Dex, Inc. and Prelude Therapeutics Incorporated across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Pro-Dex, Inc. logo
PDEX
Pro-Dex, Inc.
$209M
$65.37HealthcareDelayed quote: Oct 6, 2026, 1:54 PM EDT
Prelude Therapeutics Incorporated logo
PRLD
Prelude Therapeutics Incorporated
$212M
$3.72HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT

Total return — PDEX vs PRLD

growth of $100 · dividends reinvested · last 6y
PDEX +142.7% (+15.9%/yr)PRLD -85.6% (-27.6%/yr)PDEX compounded faster over this window
Log scale — wide-divergence pair
1101001kStart $100202120222023202420252026$243$14
PDEX PRLD

PDEX vs PRLD: by the numbers

  • •PRLD is the larger company ($212M vs $209M market cap).
  • •PDEX is profitable (17.62% net margin) while PRLD runs a net loss (-269.75%).

Metrics side by side

Valuation

MetricPDEXPRLD
P/E ratio15.87N/A
Forward P/E21.16N/A
PEG ratio0.54N/A
P/S ratio2.699.44
P/B ratio4.381.58
EV / EBITDA15.20N/A
FCF yield3.30%N/A

Profitability

MetricPDEXPRLD
Gross margin31.38%85.91%
Operating margin16.75%-861.33%
Net margin17.62%-269.75%
ROE28.68%-45.23%
ROIC14.99%-43.74%

Growth (annualized)

MetricPDEXPRLD
Revenue CAGR (5Y)15.32%N/A
EPS CAGR (5Y)29.38%N/A
Total return CAGR (5Y)20.45%-33.98%

Frequently asked

Is PDEX or PRLD more profitable?
PDEX runs the higher net margin — PDEX at 17.62% versus PRLD at -269.75%.
How have PDEX and PRLD total returns compared?
Over the past 5 years, PDEX delivered 20.45% and PRLD delivered -33.98% annualized total return. Past performance doesn't predict future results.

Go deeper

Full PDEX analysisFull PRLD analysisInteractive comparison tool

Dig into the metrics

Pro-Dex P/E ratioPro-Dex ROEPrelude Therapeutics ROEPro-Dex operating marginPrelude Therapeutics operating marginPro-Dex revenue growthPrelude Therapeutics revenue growthPro-Dex free cash flowPrelude Therapeutics free cash flow

Pro-Dex & Prelude Therapeutics appear in these rankings

Fastest Revenue Growth StocksHighest ROE StocksHighest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.